Research and Markets has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016" report to their offering.
Interstitial Cystitis (Painful Bladder Syndrome) pipeline therapeutics constitutes close to 15 molecules, out of which approximately 14 molecules are developed by Companies and the remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 4 and 1, respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.
Interstitial Cystitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/3fjnqt/interstitial.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006395/en/Business Wire
Last updated on: 20/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.